Lund, Sweden, 8 July, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January – June 2026 on 22 July, 2026. Interested parties may join the Company’s quarterly conference call on the same date at 14:00 CEST / 8:00 AM EDT. The event will be hosted by Renée Aguiar-Lucander, CEO, Adam Cutler, CFO, […]
Preclinical data demonstrate >90% reduction in human cytomegalovirus (HCMV) reactivation from latency, establishing proof-of-concept for SYN002 in human kidneys Data published in the American Journal of Transplantation and to be presented as a poster at the Cutting Edge of Transplantation (CEoT) Summit, Scottsdale, Arizona, 26–28 February 2026 Regulatory clearance granted by both UK MHRA and […]
Lund, Sweden, 18 February 2026. Hansa Biopharma AB, (“Hansa” or “the Company”), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase has been accepted by the U.S. Food and Drug Administration (FDA). FDA’s filing review was completed on day 60 which is meant to verify that the submission is substantially complete […]
Lund, Sweden, 29 October 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant surgeons; Professor Robert Montgomery from NYU Langone Transplant Institute and Professor Matthew Cooper from the Medical College of Wisconsin, to provide deeper insights into the medical journey of highly sensitized […]
At 12 months, mean eGFR was 51.5 mL/min/1.73m2 in the imlifidase arm versus 19.3 mL/min/1.73m2 in the control arm with a statistically significant and clinically meaningful difference of 32.2 mL/min/1.73m2 ( p<0.0001) Imlifidase was generally well tolerated with a safety profile consistent with previous clinical trial experience Submission of a Biologic License Application (BLA) under accelerated approval pathway […]
